Literature DB >> 7260868

Management and survival of female patients with "minimal" breast cancer: as observed in the long-term and short-term surveys of the American College of Surgeons.

R Bedwani, J Vana, D Rosner, R L Schmitz, G P Murphy.   

Abstract

The American College of Surgeons' long-term breast cancer survey in 1978 included 16,894 pathologically confirmed carcinomas of the female breast, in situ or infiltrative, with negative or positive nodes. Of these, 1.9% were in situ carcinoma of any size, and 8.4% were minimal invasive carcinomas 1 cm or less in diameter. No significant difference was found between the survival of patients with in situ tumors of any size and minimal invasive tumors with negative axillary nodes measuring 1 cm or less in diameter. In patients with invasive tumors with negative axillary lymph nodes, no statistically significant difference was found in survival of patients with tumors of 0.5 cm or less, when compared either with survival of patients with tumors measuring 0.6-1.0 cm. Recurrence rates observed in those groups were not statistically significant. Among 157 patients with invasive tumors measuring 0.5 cm or less, 23.0% presented with axillary lymph node metastasis. Tumors measuring 0.6 to 1.0 cm showed 20.9% positive axillary nodes in 964 patients. Statistically significant differences in survival and recurrence rates were achieved only for invasive tumors smaller than 1 cm. Survival and recurrence rates were significantly better (P less than 0.001) in patients with minimal invasive cancer with negative axillary nodes (P less than 0.001) than rates of patients with invasive tumors larger than 1 cm and with negative lymph nodes. Similar statistical results were obtained for patients with positive axillary nodes only for invasive cancers smaller than 1 cm. However, survival and recurrence rates observed in invasive cancers of 1 cm or less with positive axillary nodes suggest that tumor size alone cannot be used as the only defining criterion for minimal invasive breast cancer. Only the status of axillary nodes may determine whether a small invasive tumor below 1 cm may be considered as minimal breast cancer.

Entities:  

Mesh:

Year:  1981        PMID: 7260868     DOI: 10.1002/1097-0142(19810615)47:12<2769::aid-cncr2820471202>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Frequency distribution of tissue mast cells and eosinophilic granulocytes in tumor-draining axillary and paracolic lymph nodes.

Authors:  H P Horny; H A Horst
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

2.  Microscopic carcinoma of the breast--report of a case.

Authors:  M Nishiki; K Amano; M Yamane; K Yasuda; T Okumichi; H Ezaki
Journal:  Jpn J Surg       Date:  1984-05

3.  Treatment and survival of female patients with nonpalpable breast carcinoma.

Authors:  J G Tinnemans; T Wobbes; R Holland; J H Hendriks; R F Van der Sluis; H H De Boer
Journal:  Ann Surg       Date:  1989-02       Impact factor: 12.969

4.  Advantages of magnetic resonance imaging in breast surgery treatment planning.

Authors:  T E Merchant; H Obertop; P W de Graaf
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

5.  Invasive breast cancer--the tip of an iceberg.

Authors:  C J Cahill; N M Gibbs; P S Boulter; M J Brient; J L Price
Journal:  Ann R Coll Surg Engl       Date:  1983-11       Impact factor: 1.891

6.  Predicting recurrence in axillary-node negative breast cancer patients.

Authors:  D Rosner; W W Lane
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

7.  Management of nonpalpable breast abnormalities.

Authors:  R E Symmonds; J W Roberts
Journal:  Ann Surg       Date:  1987-05       Impact factor: 12.969

8.  The natural history of human breast cancer. The relationship between involvement of axillary lymph nodes and the initiation of distant metastases.

Authors:  S Koscielny; M G Le; M Tubiana
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

9.  A suggested follow-up time for breast cancer patients.

Authors:  M K Leivonen; I A Saario; P Peltokallio; L Tuominen; T V Kalima
Journal:  Br J Cancer       Date:  1986-11       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.